
Obstructive sleep apnoea is characterised by repetitive upper airway collapse during sleep, resulting in intermittent hypoxia and arousal from sleep. CPAP therapy is the most effective treatment; tirzepatide has demonstrated meaningful OSA severity reduction as part of its metabolic effects. Cardiovascular outcome data from GLP-1 receptor agonist trials in OSA are anticipated to influence management guidelines.
Loading articles...
